The syndrome may include but is not limited to genital symptoms of dryness, burning, and irritation; sexual symptoms of lack of lubrication, discomfort or pain, and impaired function; and urinary symptoms of urgency, dysuria and recurrent urinary tract infections. (1)

To gain better understanding of how GSM affects quality of life, a survey of 3,520 postmenopausal women 55 - 65 years was conducted (VIVA). The study revealed almost 50% women reported GSM symptoms.

• 82% of women felt that vaginal discomfort would have a negative impact on various aspects of their lives, most notably sexual intimacy (72%)

• 62% described their symptoms as moderate or severe

• Over half (55%) reported symptoms that lasted for 3 years or longer

 Unlike some peri-menopausal symptoms, GSM is a progressive condition and, most likely, will not resolve without intervention. Previously, therapies have been targeted at helping to manage symptoms, but the newer modalities such as fractionated CO2 laser (eg: MonaLisa) and Platelet Rich Plasma (PRP) offer a method to treat both the symptoms and the underlying cause.

 PRP is a new technique to assist management of Female Sexual Dysfunction (FSD), Vulvovaginal atrophy (VVA) and Stress Urinary Incontinence (SUI). Naturalis PRP doctors use a latest technology, TGA approved PRP system that extracts very ‘pure’ PRP with 9x baseline platelet concentration and very low leukocytes. Not all PRP is equal, and the treatment outcomes are dependent on scientifically based pre and post procedure patient care, robust technical protocols and quality and number of platelets being injected.